Previous 10 | Next 10 |
Tislelizumab is now approved in six indications in China This marks tislelizumab’s third approved lung cancer indication in China and first in a previously treated patient population The approval was supported by results from the global Phase 3 trial R...
BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of China's largest cities. Shanghai Ji Xing Pharma in-licensed Chin...
In these troubled times of U.S.-China tensions, sometimes being a copycat has its benefits. The vast majority of the many publicly listed drug makers in China are essentially copycats that license mature drugs from other, mostly western, developers to sell in China. The big news c...
BeiGene (NASDAQ:BGNE) has added ~5.2% after announcing a deal with Novartis Pharma (NYSE:NVS) to develop, manufacture and commercialize its investigational TIGIT inhibitor ociperlimab across North America, Europe, and Japan. Per the terms, the Chinese biotech company will receive $3...
Strategic collaboration expected to advance clinical development of ociperlimab in combination with tislelizumab, including initiation and funding by Novartis of additional studies BeiGene expands commercial portfolio in China broad markets with marketing rights for five Novar...
Next-generation facility will support growth of startups and accelerate early-stage innovation with state-of-the-art research infrastructure, scientific and business support BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focu...
BeiGene began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong and Shanghai. Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Ar...
Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...
News that the Federal Reserve was primed to start fighting inflation sent U.S. stocks sharply higher on Wednesday. While monetary policy served as the main driver of trading, the session still featured a wide range of single-stock stories. Pfizer (NYSE:PFE) represented one of the standout per...
Shares of BeiGene (NASDAQ: BGNE) and Zai Lab (NASDAQ: ZLAB) were down by 13% and 15%, respectively, as of 2:40 p.m. ET Wednesday. These two Chinese biotechs were getting crushed over fears that they might eventually be forced to delist from the Nasdaq stock exchange. Ris...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...